We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his children were diagnosed with a rare disease. That spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Building on our core beliefs, our mission-focused behaviors help us define and shape our culture; drive performance and innovation; inform development and growth; and attract, energize, and retain the right talent. By championing mission-dedication, innovation, performance, and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. Our global footprint spans over 20 countries, including our global headquarters in Philadelphia, PA and international headquarters in Marlow, UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain. More information about Amicus and our career opportunities can be found at www.amicusrx.com.